Capital Flow Monitor · Sponsors · CIK 2023640

Blackstone Life Sciences VI L.P.

345 PARK AVENUE, NEW YORK, NY, 10154 · 212-583-5000

Pooled Investment Fund / Private Equity Fund · Limited Partnership· inc. DELAWARE true 2023

Fit score

Offering

$6.3B

Sold

$6.3B

% sold

100.0%

Investors

119

Min investment

$0

Exemption

506(b)

Filing history

FiledFormRuleOfferingSold% soldInvestors
2026-04-02 D/A ·current 506(b) $6.3B $6.3B 100.0% 119 EDGAR ↗
2025-12-09 D/A 506(b) $3.62B 69 EDGAR ↗
2025-10-08 D/A 506(b) $3.29B 67 EDGAR ↗

Related persons

Executive officers, directors and promoters, as filed.

  • n/a Blackstone Life Sciences Associates VI L.P. — Promoter, New York, NY
  • n/a BXLS VI L.L.C. — Promoter, New York, NY
  • Joseph Baratta — Executive Officer, New York, NY
  • Alicia Novak — Executive Officer, New York, NY
  • John G. Finley — Executive Officer, New York, NY
  • Nicholas Galakatos — Executive Officer, New York, NY
  • Victoria Portnoy — Executive Officer, New York, NY
  • Eric Liaw — Executive Officer, New York, NY
  • Christopher Striano — Executive Officer, New York, NY
  • Chris Placca — Executive Officer, New York, NY
  • Elsa Gelin — Executive Officer, New York, NY
  • Omar Rehman — Executive Officer, New York, NY
  • Robert Liptak — Executive Officer, New York, NY
  • Nentcho Nentchev — Executive Officer, New York, NY
  • Mathias Favetto — Executive Officer, New York, NY
  • Ilan Halal — Executive Officer, New York, NY

Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.